Pharmaceuticals
enterpriseTarget: Drug developer
If you are a drug developer dealing with the lack of curative MS therapies — this project developed clinical trial data on antiviral therapies that could lead to a new class of MS treatments.
EBV-MS · Project
Developing Antiviral Treatments and Predictive Tools to Prevent and Treat Multiple Sclerosis
healthTestedTRL 5
Imagine a tiny virus is like a spark that starts a fire in the brain's wiring, leading to Multiple Sclerosis. This work looks for the best way to put out that spark using antiviral drugs. By studying the virus and using AI, the team wants to stop the disease before it even starts.
By the numbers
1 million
people with MS in Europe
16
consortium partners
2
clinical trials for antiviral therapies
The business problem
What needed solving
Multiple Sclerosis causes significant disability in young adults and lacks curative treatments. Current therapies manage symptoms but do not address the viral trigger, EBV, which is present in nearly all MS patients.
The solution
What was built
The project is building two clinical trials for antiviral drugs, AI-driven predictive risk models, and mathematical simulations of immune dynamics.
Audience
Who needs this
Neurology-focused pharmaceutical companiesAI-driven diagnostic developersVaccine research organizationsPublic health agencies
Business applications
Who can put this to work
Diagnostics
SMETarget: Medical AI company
If you are a medical AI company dealing with unpredictable disease onset — this project developed predictive models using machine learning that identify MS risk and progression based on viral signatures.
Public Health
enterpriseTarget: Vaccine manufacturer
If you are a vaccine manufacturer dealing with high disease burdens in young adults — this project developed evidence on the link between EBV and MS that supports the creation of preventive vaccines.
Frequently asked
Quick answers
What is the cost or price of the developed solutions?
Based on available project data, there is no information regarding the cost or pricing of the therapies or models.
Can these antiviral treatments be scaled to industrial production?
The project focuses on clinical trials and mechanistic research; industrial scaling details are not provided in the current dataset.
What is the IP or licensing strategy for the predictive models?
Based on available project data, specific IP and licensing terms have not been disclosed.
What is the timeline for clinical validation?
The project is active from 2023-12-01 to 2028-11-30, covering the period for the two planned clinical trials.
How will the AI models integrate with existing health registries?
The project utilizes high-quality health registries and existing research cohorts to train and validate its machine learning models.
Consortium
Who built it
The consortium is heavily research-oriented, consisting of 16 partners across 7 countries. It is dominated by 7 universities and 6 research institutions, with only 1 industry partner (6% ratio). This suggests the project is currently in a high-science phase, focusing on validation and discovery rather than immediate commercial rollout.
How to reach the team
Contact Universitetet i Bergen for clinical trial data and partnership opportunities.
Next steps
Talk to the team behind this work.
Contact us to bridge the gap between these clinical findings and your drug pipeline.
More in Health & Biomedical
See all Health & Biomedical projects →